ECL1i TFA is an allosteric, selective CCR2 inhibitor. ECL1i TFA specifically inhibits CCL2-/CCR2-mediated chemotaxis. ECL1i TFA interferes with CCR2-positive cell recruitment and attenuates disease progression in experimental autoimmune encephalomyelitis [1].
References:
[1]. Auvynet C, et al. ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. FASEB J. 2016 Jun;30(6):2370-81. doi: 10.1096/fj.201500116. Epub 2016 Mar 15. Erratum in: FASEB J. 2017 Feb;31(2):852.
References:
[1]. Auvynet C, et al. ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. FASEB J. 2016 Jun;30(6):2370-81. doi: 10.1096/fj.201500116. Epub 2016 Mar 15. Erratum in: FASEB J. 2017 Feb;31(2):852.